Search

Displaying results 3221 - 3230 of 10000 in total
  1. Drug

    Terevalefim

    go.drugbank.com/drugs/DB16397
    Investigational

    Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).

  2. Drug

    Scarlet red

    go.drugbank.com/drugs/DB19136
    ApprovedWithdrawn

    Scarlet red is under investigation in clinical trial NCT00591916 (New Treatment for Donor Sites).

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Peginesatide

    go.drugbank.com/drugs/DB08894
    ApprovedWithdrawn

    Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed ...

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    REN-850

    go.drugbank.com/drugs/DB05912
    Experimental

    REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.

  5. Drug

    Lufotrelvir

    go.drugbank.com/drugs/DB16514
    Investigational

    PF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was subsequently shelved as the outbreak was controlled[L31728]. … Now, it is being tested regarding the novel SARS-CoV-2 virus, including studies in conjunction with [Remdesivir] to treat COVID-19 infection; in vitro data showed synergistic effects on articles published

  6. Drug

    Flibanserin

    go.drugbank.com/drugs/DB04908
    ApprovedInvestigational

    Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. … in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.

  7. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies. … Some studies show the evidence of improving cognitive impairment in selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional and physical impairment [L2279

    Products: PMS-nylidrin Tab 6mg
  8. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients … [A275338, L54758] Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence.

  9. Drug

    Viloxazine

    go.drugbank.com/drugs/DB09185
    ApprovedInvestigationalWithdrawn

    [L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. … It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy.

  10. Drug

    Telisotuzumab

    go.drugbank.com/drugs/DB14838
    Investigational

    Telisotuzumab is under investigation in clinical trial NCT01472016 (Study of ABT-700 in Subjects With Advanced Solid Tumors).